Announcements Trials
Browse Landscape

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 17Observational 2

Sponsor

Conditions

Breast Neoplasms 468Neoplasms 316Carcinoma, Non-Small-Cell Lung 269Prostatic Neoplasms 215Colorectal Neoplasms 208Lung Neoplasms 178Multiple Myeloma 123Melanoma 110Carcinoma, Renal Cell 107Ovarian Neoplasms 94Carcinoma, Hepatocellular 78Pancreatic Neoplasms 69Urinary Bladder Neoplasms 65Stomach Neoplasms 64Neoplasm Metastasis 64Leukemia, Lymphocytic, Chronic, B-Cell 62Colonic Neoplasms 60Leukemia, Myeloid, Acute 53Uterine Cervical Neoplasms 50Recurrence 50Liver Neoplasms 46Lymphoma, Follicular 45Lymphoma 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 37Esophageal Neoplasms 37Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 35Head and Neck Neoplasms 35Lymphoma, Non-Hodgkin 34

Interventions

pexidartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Giant Cell Tumor of Tendon Sheath × Clear all
NCT07075471 2025-11-05

Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Deciphera Pharmaceuticals, LLC

Recruiting
100 enrolled

Giant Cell Tumor of Tendon Sheath

NCT04635111 2025-10-06

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIOâ„¢ (Pexidartinib) Treatment

Daiichi Sankyo

Recruiting
30 enrolled

Giant Cell Tumor of Tendon Sheath

Data powered by HemOnc (CC BY 4.0) Colophon âš¡